Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

Bousquet, 2020 OBSanticoagulant, curative dosecontrolCOVID 19 hospitalizedNA
-/- suggested -56%

COVID-19 severe or critically meta-analysis

REMAP-CAP, ACTIV-4a, ATTACC severe patients, 2021
 
NCT02735707
RCTanticoagulant, curative dosecontrolCOVID-19 severe or criticallysome concern
529/545 inconclusive 4% -12%
REMAP-CAP, ACTIV-4a, ATTACC severe patients, 2021
 
NCT02735707
RCTanticoagulant, curative doseanticoagulant, prophylactic doseCOVID-19 severe or criticallysome concern
529/545 inconclusive 4% -12%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).